Opdivo Injection
Product Images NDC 0003-3756

Product Visual Gallery

This gallery contains 31 technical images submitted to the FDA as part of the official labeling for Opdivo (NDC 0003-3756). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by E.r. Squibb & Sons, L.l.c., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 05

The provided text shows a graph with probability of survival on the y-axis and overall survival in months on the x-axis. However, some of the text is not properly recognized due to the error.*

FDA Label Image

Opdivo-100mg-10ml-pdp (Opdivo 100mg 10ml Pdp)

This is a warning label for an intravenous medication called "nvokimad". It cautions users not to use if the bottle, carton, or seal is damaged, and to only use it as directed by a physician. The medication contains 100mg of nvokimad per 10 mL of solution, along with other ingredients. The label outlines storage instructions for the medication, such as refrigerating it between uses and avoiding shaking or freezing the bottle.*

FDA Label Image

Opdivo 120mg 12ml Pdp

This is a description for a medication provided in a single dose vial. The product should not be used if the vial seal is broken or missing, or if the carton or carton flaps are torn or ripped. The medication is produced by Bristol Myers Squibb and is for intravenous infusion only. It contains 120 mg of the drug in 12 mL of solution and is administered through an intravenous line. The medication includes several other ingredients to adjust its pH and maintain its stability. The medication must be infused within 24 hours of preparation, and it should be refrigerated between 2-5°C until use. The dosage and administration information is provided in the prescribing information.*

FDA Label Image

Opdivo-240mg-24ml-pdp (Opdivo 240mg 24ml Pdp)

This is a description of a pharmaceutical product made by Bristol Myers Squibb CO. It contains a single-dose vial that is only for intravenous infusion. The product should not be used if the carton or carton flaps are torn or ripped. The ingredients include nivolumab, pentetic acid, polysorbate 80, sodium chloride, sodium citrate dihydrate, and water for injection. The administration should be through an intravenous non-pyrogenic low-potency binding-filtration device and completed within 24 hours of preparation. The product should be stored in a refrigerator at 2°C-5°C and protected from light in its original package.*

FDA Label Image

Opdivo-40mg-4ml-pdp (Opdivo 40mg 4ml Pdp)

This is a medication warning label for a 40 mg/4 ml vial of Nivolumab. It is for intravenous infusion only. The label warns against using the product if the carton or carton flaps are torn, missing, or ripped. The medication should be discarded after use, and it should be protected from light. Dosage information is provided in the prescribing information, and the medication should be administered through a non-pyrogenic, low protein binding inline filter. The medication should be stored at 2°C to 8°C and should not be frozen or shaken.*

FDA Label Image

Opdivo Dfs Checkmate 274

Not available.*

FDA Label Image

Opdivo-dfs-checkmate-577.jpg (Opdivo Dfs Checkmate 577)

FDA Label Image

Opdivo Efs Checkmate 816

FDA Label Image

Opdivo-forest-os-checkmate-057.jpg (Opdivo Forest Os Checkmate 057)

This appears to be a statistical table or chart related to treatment outcomes with two drugs OPDIVO and Docetaxel. It includes information about PD-L1 expression and median time periods in months. However, due to the lack of context and clear readability, a detailed description cannot be provided.*

FDA Label Image

Opdivo-forest-pfs-checkmate-057.jpg (Opdivo Forest Pfs Checkmate 057)

This is a study showing the median PFS (progression-free survival) in months for patients with PD-L1 expression level of 21% treated with OPDIVO and Docetaxel. The unstratified HR (hazard ratio) is also included in the table. However, no additional information or context is given, so it is unclear what the study is about or what the results mean.*

FDA Label Image

Opdivo-os-all-patients-checkmate-649.jpg (Opdivo Os All Patients Checkmate 649)

This appears to be a graph showing the probability of overall survival for subjects receiving OPDIVO in addition to chemotherapy versus those receiving only chemotherapy. The X-axis represents the number of subjects at specific time intervals and the Y-axis represents the duration of overall survival in months. The graph shows that the probability of overall survival is higher for subjects receiving OPDIVO in addition to chemotherapy compared to those receiving only chemotherapy. However, the data is truncated and incomplete as there is not enough information provided to interpret the graph accurately.*

FDA Label Image

Opdivo-os-checkmate-017.jpg (Opdivo Os Checkmate 017)

FDA Label Image

Opdivo-os-checkmate-025.jpg (Opdivo Os Checkmate 025)

FDA Label Image

Opdivo-os-checkmate-037 (Opdivo Os Checkmate 037)

This appears to be a table displaying the Probability of Survival for a particular study or clinical trial. The dates or years may be represented in the first column, with corresponding survival rates in the subsequent columns. There is a section header labeled "Investigator's Choice" which may refer to a specific treatment group or intervention. The last row contains numerical values for the number of subjects at risk and their overall survival, measured in months. The origin or context of the table is not clear.*

FDA Label Image

Opdivo-os-checkmate-057.jpg (Opdivo Os Checkmate 057)

Not available.*

FDA Label Image

Opdivo-os-checkmate-066.jpg (Opdivo Os Checkmate 066)

This is a chart that shows the probability of survival over a certain number of months for two different treatments: one with the drug Dacarbazine and another treatment labeled as TR. The chart has numbered intervals on the horizontal axis and months on the vertical axis. The TR treatment appears to have a slightly higher probability of survival at the beginning, but the Dacarbazine treatment becomes more effective after three months.*

FDA Label Image

Opdivo-os-checkmate-067 (Opdivo Os Checkmate 067)

This appears to be a table that compares the survival rates of several subjects using different treatments. The treatments being compared are OPDIVO, OPDIVO + Ipiimumab, and Iplimumab. The table shows the number of subjects at different overall survival months.*

FDA Label Image

Opdivo-os-checkmate-141.jpg (Opdivo Os Checkmate 141)

FDA Label Image

Opdivo-os-checkmate-214.jpg (Opdivo Os Checkmate 214)

The generated text is a chart depicting the overall survival rates in months for two treatment options, OPDIVO + ipilimumab and Sunitinib. The chart also shows the number of subjects at risk for each treatment option.*

FDA Label Image

Opdivo-os-checkmate-227 (Opdivo Os Checkmate 227)

This is a graph showing the probability of overall survival for two groups of subjects, one treated with OPDVO and ipilimumab and the other group with platinum-doublet chemotherapy. The X-axis represents the months elapsed since the start of treatment and the Y-axis represents the number of subjects who survived.*

FDA Label Image

Opdivo Os Checkmate 648 A

FDA Label Image

Opdivo Os Checkmate 648 B

FDA Label Image

Opdivo-os-checkmate-743.jpg (Opdivo Os Checkmate 743)

This text provides data on the probability of overall survival in subjects treated with OPDIVO+ipilimumab and chemotherapy. The data includes the number of subjects at risk, overall survival (in months), and the treatment method used.*

FDA Label Image

Opdivo-os-checkmate-9er.jpg (Opdivo Os Checkmate 9er)

FDA Label Image

Opdivo-os-checkmate-9la.jpg (Opdivo Os Checkmate 9la)

FDA Label Image

Opdivo-os-pd-l1-cps-1-or-greater-checkmate-649.jpg (Opdivo Os Pd L1 Cps 1 Or Greater Checkmate 649)

FDA Label Image

Opdivo-os-pd-l1-cps-5-or-greater-checkmate-649.jpg (Opdivo Os Pd L1 Cps 5 Or Greater Checkmate 649)

FDA Label Image

Opdivo Pfs Checkmate 648 A

FDA Label Image

Opdivo Pfs Checkmate 648 B

FDA Label Image

Opdivo-pfs-checkmate-9er.jpg (Opdivo Pfs Checkmate 9er)

The text provides a chart displaying the probability of progression-free survival per BICR for two treatments (OPDIVO + Cabozantinib and Sunitinib) over a period of months. The number of subjects at risk is also shown for each treatment. No further information is available.*

FDA Label Image

Opdivo-rfs-checkmate-238 (Opdivo Rfs Checkmate 238)

This appears to be a survival analysis table showing the probability of recurrence-free survival for subjects receiving treatment with ipilimumab. The table also includes the number of subjects at risk at each time point.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.